Centocor Research & Development, Inc. clinical trials

A subsidiary of Johnson & Johnson

The registry lists 4 studies whose lead sponsor is Centocor Research & Development, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jun 24, 2013.

Status

Completed: 4

Phase

Phase 3: 2
Phase 2: 1
Phase 1: 1

Where

United States: 3
Belgium: 2
Canada: 2
United Kingdom: 2
Russian Federation: 1
Germany: 1

Registry sponsor names on this page

Centocor Research & Development, Inc.4 studies

Something wrong with this grouping? Tell us on the Johnson & Johnson page.

Studies

Recruiting first, then most recently updated. Showing 4 of 4. All Johnson & Johnson studies →

A Study of the Safety and Efficacy of Single-agent Carlumab (an Anti-Chemokine Ligand 2 [CCL2]) in Participants With Metastatic Castrate-Resistant Prostate CancerCompletedNCT00992186Phase 2
Sponsor listed in the registry: Centocor Research & Development, Inc.
A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type PsoriasisCompletedNCT00267969Phase 3
Sponsor listed in the registry: Centocor Research & Development, Inc.
A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe PsoriasisCompletedNCT00307437Phase 3
Sponsor listed in the registry: Centocor Research & Development, Inc.
A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus ErythematosusCompletedNCT01702740Phase 1
Sponsor listed in the registry: Centocor Research & Development, Inc.